Coya Therapeutics (NASDAQ:COYA - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.10 million. On average, analysts expect Coya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Coya Therapeutics Stock Performance
Shares of Coya Therapeutics stock traded up $0.09 on Friday, reaching $6.37. 37,675 shares of the company's stock were exchanged, compared to its average volume of 72,881. The company has a market capitalization of $106.54 million, a P/E ratio of -9.80 and a beta of 0.49. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24. The firm's 50-day moving average is $6.18 and its two-hundred day moving average is $6.36.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the stock. D. Boral Capital restated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday, April 22nd. Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Monday, April 28th.
Read Our Latest Stock Analysis on Coya Therapeutics
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Featured Articles
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
